Literature DB >> 8092761

Plasma endothelin-1 in the neonatal respiratory distress syndrome.

P Kääpä1, P Kero, H Ekblad, R Erkkola, O Arjamaa.   

Abstract

In order to study the contribution of the vasoconstrictory peptide endothelin-1 (ET-1) to the elevation of the pulmonary vascular resistance in the neonatal respiratory distress syndrome (RDS) seven preterm infants were studied at 2, 24 and 48 hours of age for plasma ET-1 concentrations and systolic pulmonary artery pressure (PAP), measured by Doppler sonography. Plasma ET-1 levels were high during the first day after birth, but declined soon to normal levels thereafter. During the study period, the systolic PAP also decreased, whereas the systemic pressure remained unchanged. There were no correlations between plasma ET-1 and vascular pressures, but there was a significant association between ET-1 and the requirement of supplemental oxygen and the arterial-alveolar oxygen tension ratio. Our results thus suggest that high plasma ET-1 levels in the acute phase of RDS reflect the severity of the pulmonary disease, but may not significantly contribute to the elevation of the pulmonary vascular resistance in the RDS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8092761

Source DB:  PubMed          Journal:  Ann Chir Gynaecol Suppl        ISSN: 0355-9874


  3 in total

Review 1.  Factors relating caesarean section to persistent pulmonary hypertension of the newborn.

Authors:  Niralee Babooa; Wen-Jing Shi; Chao Chen
Journal:  World J Pediatr       Date:  2017-10-20       Impact factor: 2.764

2.  Does endothelin-1 reduce superior mesenteric artery blood flow velocity in preterm neonates?

Authors:  F J Weir; A Ohlsson; K Fong; K Amankwah; F Coceani
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1999-03       Impact factor: 5.747

3.  Serum endothelin-1 and transforming growth factor-beta levels in the newborns with respiratory distress.

Authors:  Derya Benzer; A Denizmen Aygun; Ahmet Godekmerdan; A Nese Citak Kurt; Saadet Akarsu; Erdal Yilmaz
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.